111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
微针联合氨甲环酸-熊果苷液体辅料治疗黄褐斑的疗效及安全性评估：一项回顾性研究
Authors Zhang M , Ke J, Jiao Y , Ma L
Received 1 August 2025
Accepted for publication 5 November 2025
Published 25 November 2025 Volume 2025:18 Pages 3147—3154
DOI https://doi.org/10.2147/CCID.S542746
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Jeffrey Weinberg
Mingli Zhang, Jincheng Ke, Yunhe Jiao, Li Ma
Dermatology Department, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, People’s Republic of China
Correspondence: Mingli Zhang, Email zhangmingli@xmmc.edu.cn
Background: The condition of melasma presents a complex pigmented skin disorder, characterized by increased production of melanin in the dermis. The main pathological change of melasma is photodamage to the dermis. The treatment of melasma is relatively complex, and tranexamic acid is a well-known drug, both topical and oral. While arbutin demonstrates notable skin brightening effects, it has not yet gained widespread clinical adoption. Microneedle therapy, however, not only enhances drug penetration and absorption but also stimulates tissue regeneration. Nevertheless, research on the combined application of tranexamic acid, arbutin, and microneedle therapy for melasma treatment remains limited.
Methods: A single-center retrospective dermatology study (Jan 2022–Jun 2023, n=27) evaluated microneedling plus tranexamic acid-arbutin solution for melasma. Medical records of 27 patients (3– 6 months of treatment) were analyzed; efficacy was assessed via mMASI and PGA scores by two dermatologists, with side effect analysis.
Results: Before treatment, the average mMASI score of 27 patients with melasma was 5.426± 2.128. After treatment with microneedling combined with tranexamic acid and arbutin liquid adjuncts, the mMASI score was 3.387± 1.224, showing a mean decrease of 2.039± 1.472 (37.58%). In terms of the PGA score, 20 patients achieved a score of 3 or higher (overall rate: 74.07%). The observed adverse reactions mainly include temporary erythema, burning sensation, petechiae (or/and ecchymosis), and skin dryness. The first two are more common but are mild in severity, with most cases resolving within hours; petechiae (or/and ecchymosis) and skin dryness are less common, and no cases of skin infection have been found.
Conclusion: Microneedling combined with tranexamic acid-arbutin liquid adjuvant treatment for melasma is feasible and well-tolerated. Its side effects are relatively few, but it is still recommended to appropriately adjust the treatment intervals, intensity, and density, or combine it with other methods to enhance efficacy.
Keywords: arbutin, melasma, Mesoderm therapy, microneedle, tranexamic acid
Dermatology Department, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, People’s Republic of China
Correspondence: Mingli Zhang, Email zhangmingli@xmmc.edu.cn
Background: The condition of melasma presents a complex pigmented skin disorder, characterized by increased production of melanin in the dermis. The main pathological change of melasma is photodamage to the dermis. The treatment of melasma is relatively complex, and tranexamic acid is a well-known drug, both topical and oral. While arbutin demonstrates notable skin brightening effects, it has not yet gained widespread clinical adoption. Microneedle therapy, however, not only enhances drug penetration and absorption but also stimulates tissue regeneration. Nevertheless, research on the combined application of tranexamic acid, arbutin, and microneedle therapy for melasma treatment remains limited.
Methods: A single-center retrospective dermatology study (Jan 2022–Jun 2023, n=27) evaluated microneedling plus tranexamic acid-arbutin solution for melasma. Medical records of 27 patients (3– 6 months of treatment) were analyzed; efficacy was assessed via mMASI and PGA scores by two dermatologists, with side effect analysis.
Results: Before treatment, the average mMASI score of 27 patients with melasma was 5.426± 2.128. After treatment with microneedling combined with tranexamic acid and arbutin liquid adjuncts, the mMASI score was 3.387± 1.224, showing a mean decrease of 2.039± 1.472 (37.58%). In terms of the PGA score, 20 patients achieved a score of 3 or higher (overall rate: 74.07%). The observed adverse reactions mainly include temporary erythema, burning sensation, petechiae (or/and ecchymosis), and skin dryness. The first two are more common but are mild in severity, with most cases resolving within hours; petechiae (or/and ecchymosis) and skin dryness are less common, and no cases of skin infection have been found.
Conclusion: Microneedling combined with tranexamic acid-arbutin liquid adjuvant treatment for melasma is feasible and well-tolerated. Its side effects are relatively few, but it is still recommended to appropriately adjust the treatment intervals, intensity, and density, or combine it with other methods to enhance efficacy.
Keywords: arbutin, melasma, Mesoderm therapy, microneedle, tranexamic acid